BMS-911543   Click here for help

GtoPdb Ligand ID: 7954

Synonyms: BMS 911543 | BMS911543
PDB Ligand
Compound class: Synthetic organic
Comment: BMS-911543 is an orally available ATP-competitive inhibitor of Janus kinase 2 (JAK2) with potential antineoplastic activity. Its discovery is described by Purandare et al. (2012) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 85.8
Molecular weight 432.24
XLogP 3.7
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCn1c(cc2c1nc(Nc1nn(c(c1)C)C)c1c2n(C)cn1)C(=O)N(C1CC1)C1CC1
Isomeric SMILES CCn1c(cc2c1nc(Nc1nn(c(c1)C)C)c1c2n(C)cn1)C(=O)N(C1CC1)C1CC1
InChI InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27)
No information available.
Summary of Clinical Use Click here for help
A multiple ascending dose Phase 1/II clinical trial is underway in patients with myelofibrosis (NCT01236352).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
JAK2 is often upregulated or mutated in several types of cancer cells. This induces signal transducer and activator of transcription 3 (STAT3) activation and plays a key role in tumour cell proliferation and survival. Therfore, inhbition of JAK2 prevents this abberant activation of the JAK/STAT signaling cascade and may lead to an induction of tumour cell apoptosis and a decrease in cellular proliferation.